Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura.

MLA

Stasi, Roberto, et al. “Response to B-Cell Depleting Therapy with Rituximab Reverts the Abnormalities of T-Cell Subsets in Patients with Idiopathic Thrombocytopenic Purpura.” Blood, vol. 110, no. 8, Oct. 2007, pp. 2924–30. EBSCOhost, https://doi.org/10.1182/blood-2007-02-068999.

APA

Stasi, R., Del Poeta, G., Stipa, E., Evangelista, M. L., Trawinska, M. M., Cooper, N., & Amadori, S. (2007). Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood, 110(8), 2924–2930. https://doi.org/10.1182/blood-2007-02-068999

Chicago

Stasi, Roberto, Giovanni Del Poeta, Elisa Stipa, Maria Laura Evangelista, Margherita M Trawinska, Nichola Cooper, and Sergio Amadori. 2007. “Response to B-Cell Depleting Therapy with Rituximab Reverts the Abnormalities of T-Cell Subsets in Patients with Idiopathic Thrombocytopenic Purpura.” Blood 110 (8): 2924–30. doi:10.1182/blood-2007-02-068999.